SelectiveROCK2 inhibition in focal cerebral ischemia
Open Access
- 19 November 2013
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 1 (1), 2-14
- https://doi.org/10.1002/acn3.19
Abstract
Objective Rho‐associated kinase (ROCK) is a key regulator of numerous processes in multiple cell types relevant in stroke pathophysiology. ROCK inhibitors have improved outcome in experimental models of acute ischemic or hemorrhagic stroke. However, the relevant ROCK isoform (ROCK1 or ROCK2) in acute stroke is not known. Methods We characterized the pharmacodynamic and pharmacokinetic profile, and tested the efficacy and safety of a novel selective ROCK2 inhibitor KD025 (formerly SLx‐2119) in focal cerebral ischemia models in mice. Results KD025 dose‐dependently reduced infarct volume after transient middle cerebral artery occlusion. The therapeutic window was at least 3 h from stroke onset, and the efficacy was sustained for at least 4 weeks. KD025 was at least as efficacious in aged, diabetic or female mice, as in normal adult males. Concurrent treatment with atorvastatin was safe, but not additive or synergistic. KD025 was also safe in a permanent ischemia model, albeit with diminished efficacy. As one mechanism of protection, KD025 improved cortical perfusion in a distal middle cerebral artery occlusion model, implicating enhanced collateral flow. Unlike isoform‐nonselective ROCK inhibitors, KD025 did not cause significant hypotension, a dose‐limiting side effect in acute ischemic stroke. Interpretation Altogether, these data show that KD025 is efficacious and safe in acute focal cerebral ischemia in mice, implicating ROCK2 as the relevant isoform in acute ischemic stroke. Data suggest that selective ROCK2 inhibition has a favorable safety profile to facilitate clinical translation.Keywords
This publication has 47 references indexed in Scilit:
- ROCKs as immunomodulators of strokeEmerging Therapeutic Targets, 2012
- Migraine Mutations Increase Stroke Vulnerability by Facilitating Ischemic DepolarizationsCirculation, 2012
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLoS Biology, 2010
- Rho-Associated Kinase II (ROCKII) Limits Axonal Growth after Trauma within the Adult Mouse Spinal CordJournal of Neuroscience, 2009
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatinBlood Coagulation & Fibrinolysis, 2008
- ROCK1 mediates leukocyte recruitment and neointima formation following vascular injuryJCI Insight, 2008
- Cardiovascular effects of a novel potent and highly selective azaindole‐based inhibitor of Rho‐kinaseBritish Journal of Pharmacology, 2007
- Rho-Kinase Inhibition Acutely Augments Blood Flow in Focal Cerebral Ischemia via Endothelial MechanismsJournal of Cerebral Blood Flow & Metabolism, 2006
- Distribution of Rho-Kinase in the Bovine BrainBiochemical and Biophysical Research Communications, 1999